HRP20150890T1 - Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom - Google Patents

Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom Download PDF

Info

Publication number
HRP20150890T1
HRP20150890T1 HRP20150890TT HRP20150890T HRP20150890T1 HR P20150890 T1 HRP20150890 T1 HR P20150890T1 HR P20150890T T HRP20150890T T HR P20150890TT HR P20150890 T HRP20150890 T HR P20150890T HR P20150890 T1 HRP20150890 T1 HR P20150890T1
Authority
HR
Croatia
Prior art keywords
treatment
brain metastases
combination
chemotherapy agent
cytotoxic chemotherapy
Prior art date
Application number
HRP20150890TT
Other languages
English (en)
Croatian (hr)
Inventor
Isaiah J. Fidler
Sun-Jin Kim
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150890(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of HRP20150890T1 publication Critical patent/HRP20150890T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
HRP20150890TT 2009-08-10 2010-08-09 Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom HRP20150890T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10
PCT/US2010/044832 WO2011019630A2 (en) 2009-08-10 2010-08-09 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors
EP10742690.0A EP2464218B1 (en) 2009-08-10 2010-08-09 Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent

Publications (1)

Publication Number Publication Date
HRP20150890T1 true HRP20150890T1 (hr) 2015-09-25

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150890TT HRP20150890T1 (hr) 2009-08-10 2010-08-09 Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom

Country Status (27)

Country Link
US (2) US8999934B2 (online.php)
EP (1) EP2464218B1 (online.php)
JP (1) JP2013501791A (online.php)
KR (1) KR20120088665A (online.php)
CN (1) CN102510719B (online.php)
AU (1) AU2010282744B2 (online.php)
BR (1) BR112012003103A2 (online.php)
CA (1) CA2770397A1 (online.php)
CL (1) CL2012000333A1 (online.php)
DK (1) DK2464218T3 (online.php)
EA (1) EA023864B1 (online.php)
ES (1) ES2543280T3 (online.php)
HR (1) HRP20150890T1 (online.php)
HU (1) HUE026005T2 (online.php)
IL (1) IL217915A0 (online.php)
IN (1) IN2012DN01261A (online.php)
MA (1) MA33571B1 (online.php)
MX (1) MX2012001562A (online.php)
NZ (1) NZ598078A (online.php)
PL (1) PL2464218T3 (online.php)
PT (1) PT2464218E (online.php)
SG (1) SG178828A1 (online.php)
SI (1) SI2464218T1 (online.php)
TN (1) TN2012000054A1 (online.php)
TW (1) TWI483938B (online.php)
WO (1) WO2011019630A2 (online.php)
ZA (1) ZA201200980B (online.php)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501461A1 (en) * 2011-02-04 2019-03-22 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme
AU2012273182A1 (en) 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
AU2016229295B2 (en) * 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
MX2018001507A (es) 2015-08-03 2018-09-18 Enb Therapeutics Llc Composiciones y metodos para tratar cánceres asociados con la activacion del etbr.
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
WO2017209272A1 (ja) * 2016-06-03 2017-12-07 国立大学法人東京大学 がん転移阻害剤
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
WO2018152340A1 (en) 2017-02-15 2018-08-23 The Regents Of The University Of California Compositions and methods for activating nk cells
CN111886010A (zh) 2018-01-12 2020-11-03 Enb治疗公司 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
CN113874364B (zh) 2019-05-22 2024-04-05 无锡智康弘义生物科技有限公司 一种嘧啶磺酰胺类化合物的晶型及其制备方法
CN112062857B (zh) * 2019-06-10 2024-08-09 鸿运华宁（杭州）生物医药有限公司 Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
WO2021062027A1 (en) * 2019-09-25 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Thalamic input to orbitofrontal cortex drives brain-wide, frequency-dependent inhibition mediated by gaba and zona incerta
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053557A1 (en) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
WO2007031933A2 (en) * 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CN101939001B (zh) 2008-02-20 2012-06-20 埃科特莱茵药品有限公司 用于治疗卵巢癌的含有紫杉醇的组合
PH12013501461A1 (en) 2011-02-04 2019-03-22 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme

Also Published As

Publication number Publication date
TW201109315A (en) 2011-03-16
EA201270264A1 (ru) 2013-02-28
MA33571B1 (fr) 2012-09-01
PT2464218E (pt) 2015-09-16
IN2012DN01261A (online.php) 2015-05-15
EP2464218A2 (en) 2012-06-20
CN102510719B (zh) 2015-07-22
WO2011019630A3 (en) 2011-06-03
NZ598078A (en) 2013-07-26
TWI483938B (zh) 2015-05-11
ZA201200980B (en) 2012-10-31
CA2770397A1 (en) 2011-02-17
US20150352113A1 (en) 2015-12-10
IL217915A0 (en) 2012-03-29
EP2464218B1 (en) 2015-05-27
AU2010282744A1 (en) 2012-03-22
ES2543280T3 (es) 2015-08-17
WO2011019630A2 (en) 2011-02-17
SI2464218T1 (sl) 2015-10-30
US20120144510A1 (en) 2012-06-07
HK1171336A1 (en) 2013-03-28
EA023864B1 (ru) 2016-07-29
BR112012003103A2 (pt) 2016-04-19
DK2464218T3 (en) 2015-07-20
CL2012000333A1 (es) 2013-01-25
PL2464218T3 (pl) 2015-12-31
TN2012000054A1 (en) 2013-09-19
US8999934B2 (en) 2015-04-07
KR20120088665A (ko) 2012-08-08
CN102510719A (zh) 2012-06-20
JP2013501791A (ja) 2013-01-17
HUE026005T2 (en) 2016-04-28
SG178828A1 (en) 2012-04-27
MX2012001562A (es) 2013-01-29
AU2010282744B2 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
HRP20200696T1 (hr) Terapija u kombinaciji s inhibitorom topoizomeraze
MY162514A (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
HRP20211177T1 (hr) Korteksolon 17alfa-valerat za uporabu u liječenju tumora
MX363178B (es) Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados.
IL242168A0 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
CL2012000333A1 (es) Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico.
NZ707477A (en) Activin-actrii antagonists and uses for treating bone and other disorders
EP3412668A3 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX345535B (es) Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
CL2014000833A1 (es) Composicion para ser usada en la promocion del crecimiento de hueso sano y/o en la prevencion y/o tratamiento de la enfermedad osea
TN2009000451A1 (en) Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12016502353A1 (en) Pharmaceutical composition
PH12016502352A1 (en) Pharmaceutical composition
GB201204263D0 (en) Giloma treatment
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
SI3009133T1 (sl) Farmacevtski sestavek za uporabo pri zdravljenju ali preprečevanju vitaminsko-mineralnih pomanjkljivosti pri pacientih, ki so bili podvrženi želodčni by-pass-operaciji
MX2009004178A (es) Conjugados peptidicos citotoxicos.
EA201491010A1 (ru) Варианты остеопонтина для применения в подавлении или предупреждении опухолевого роста и композиции, содержащие такие варианты остеопонтина